NAA40 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL13599640	0.68	9/20
SCHEMBL13599670	0.68	9/20
SCHEMBL22331063	0.59	9/20
SCHEMBL22331064	0.59	9/20
SCHEMBL29393724	0.46	8/20
Trifluoroacetic Acid (SCHEMBL29420158)	0.74	6/20
SCHEMBL13599602	0.72	5/20
SCHEMBL13599635	0.62	3/20
SCHEMBL12914894	0.54	3/20
SCHEMBL12914897	0.52	3/20
SCHEMBL12461097	0.47	3/20
SCHEMBL13599651	0.60	2/20
Pexiganan (SCHEMBL3486378)	0.43	2/20
SCHEMBL19211093	0.79	1/20
SCHEMBL29359401	0.79	1/20
SCHEMBL1370748	0.78	1/20
SCHEMBL20815907	0.78	1/20
SCHEMBL30361785	0.78	1/20
SCHEMBL30991360	0.78	1/20
SCHEMBL28017929	0.76	1/20

Clinical trials — most relevant to NAA40 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Effect of GET73 on MRS Measures of Central Glutamate and GABA in Individuals With Alcohol Use Disorder	PHASE2	COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer	PHASE2	UNKNOWN
Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder	PHASE2	WITHDRAWN
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia	PHASE2	COMPLETED
Sirtuin-NAD Activator in Alzheimer's Disease	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia	PHASE2	ACTIVE_NOT_RECRUITING
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients	PHASE2	COMPLETED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry	nan	NOT_YET_RECRUITING
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia	nan	RECRUITING
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Biomarker for Niemann Pick Type C Disease (BioNPC)	nan	WITHDRAWN
MOLECULAR REGULATION OF MUSCLE GLUCOSE METABOLISM (AIMS 2A, 2B, 3)	nan	UNKNOWN
The Classification and Cause of Leukodystrophies of Unknown Cause	nan	COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Identification of New FTLD Genes	nan	UNKNOWN
Induced Pluripotent Stem Cells for Niemann Pick Disease	nan	COMPLETED
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS	nan	RECRUITING
Identification of a New Gene Involved in Hereditary Lipodystrophy	nan	COMPLETED
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Search for Genes Influencing Childhood Absence Epilepsy (CAE) Study	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NAA40 binder may also engage these)

Protein	Name	Similarity
Q8VE10	—	1.000	Q8VE10 →
Q568K5	—	0.976	Q568K5 →
A0MQH0	—	0.952	A0MQH0 →
Q4R4U1	—	0.952	Q4R4U1 →
Q5R5F8	—	0.951	Q5R5F8 →
Q6TUI4	—	0.951	Q6TUI4 →
Q9CZW5	—	0.950	Q9CZW5 →
Q9NVE7	—	0.950	Q9NVE7 →
Q8R418	—	0.948	Q8R418 →
Q75Q39	—	0.948	Q75Q39 →
Q6TV19	—	0.948	Q6TV19 →
Q923S8	—	0.948	Q923S8 →
Q9UPY3	—	0.947	Q9UPY3 →
A0A974H8H3	—	0.946	A0A974H8H3 →
Q6DFV5	—	0.945	Q6DFV5 →
A0A8J1LLF7	—	0.945	A0A8J1LLF7 →
HAT1	Histone acetyltransferase type B catalytic subunit	0.943	landscape →
Q96JC1	—	0.943	Q96JC1 →
Q5E964	—	0.943	Q5E964 →
B5KFI0	—	0.942	B5KFI0 →
Q6PC62	—	0.942	Q6PC62 →
Q96JJ3	—	0.942	Q96JJ3 →
Q6P1X5	—	0.942	Q6P1X5 →
P11497	—	0.942	P11497 →
B3DLA6	—	0.942	B3DLA6 →
Q5SWU9	—	0.941	Q5SWU9 →
Q9WVJ2	—	0.941	Q9WVJ2 →
PSMD13	26S proteasome non-ATPase regulatory subunit 13	0.941	landscape →
O35969	—	0.941	O35969 →
P11029	—	0.941	P11029 →